Skip to main content
SpringerLink
Log in

Adalimumab/secukinumab

Exacerbation of gastro-intestinal Behcet disease and lack of efficacy: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Chiu N, et al. Potential flare up of gastrointestinal Behcet's disease after treatment with anti-interleukin 17a therapy. International Journal of Rheumatic Diseases 26 (Suppl. 1): 37, Jan 2023. Available from: URL: http://doi.org/10.1111/1756-185X.14505 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/secukinumab. Reactions Weekly 1945, 24 (2023). https://doi.org/10.1007/s40278-023-34105-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-34105-z

Search

Navigation